Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECOVER-AUTONOMIC
NCT06305780Phase 2Completed
- Sponsor
- Kanecia Obie Zimmerman
- Start
- Mar 2024
- Primary completion
- Jul 2025
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of intravenous immunoglobulin G, ivabradine in post-COVID-19 condition (PCC), autonomic dysfunction, postural orthostatic tachycardia syndrome (POTS), sponsored by Kanecia Obie Zimmerman. Started Mar 2024; status: completed.
02
Drugs
intravenous immunoglobulin Givabradine
03
Conditions
post-COVID-19 condition (PCC)autonomic dysfunctionpostural orthostatic tachycardia syndrome (POTS)
Beyond the preview
Go deeper on NCT06305780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06305780.